迫切需要理解和预防淋球菌感染:从实验室到现实世界
淋病奈瑟菌全球广泛流行,原发预防不成功且抗菌药物耐药威胁最佳管理,无特异性疫苗,自然感染研究显示淋球菌可逃避和抑制免疫反应。含外膜囊泡(OMV)的B群脑膜炎奈瑟菌疫苗真实世界证据显示淋病病例减少,但首个随机试验未显示统计学显著的疫苗效力,候选疫苗抗原仍在临床前评估。
要点
- 淋球菌全球广泛流行,原发预防不成功,抗菌药物耐药威胁最佳管理。
- 自然感染研究显示淋球菌可逃避和抑制免疫反应,无特异性疫苗。
- 含OMV的MenB疫苗真实世界证据显示淋病病例减少,但首个随机试验未显示统计学显著疫苗效力。
核心结论
- 迫切需要理解和预防淋球菌感染,从实验室到现实世界。
研究设计与样本
- 原文未报告研究设计。
主要发现
- 淋球菌通过Th17途径诱导强烈炎症反应,大量中性粒细胞和炎性细胞因子涌入,但逃避巨噬细胞。
- Th1和Th2介导的反应被抑制,导致抗体滴度低且短暂。
- 真实世界证据提示含OMV的MenB疫苗接种者中淋病病例减少。
- 首个含OMV的MenB疫苗针对淋球菌感染的随机试验未显示统计学显著的疫苗效力。
- 几种候选疫苗抗原正在临床前评估,仅一种进入临床试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 首个含OMV的MenB疫苗针对淋球菌感染的随机试验未显示统计学显著的疫苗效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neisseria gonorrhoeae is widespread globally. Primary prevention is unsuccessful and antimicrobial resistance threatens optimal management. There is no specific vaccine and natural infection studies show that N gonorrhoeae can avoid and suppress immune responses. In addition to extensive variation in expression and specificity of many gonococcal surface antigens, it induces a robust inflammatory response through the Th17 pathway with a large influx of neutrophils and inflammatory cytokines but evades macrophages. The Th1- and Th2-mediated response is suppressed, resulting in low, short-lived antibody titers. Real-world evidence suggests that gonorrhea cases are reduced among recipients of Neisseria meningitidis group B vaccines containing outer membrane vesicles (OMVs). Although the first randomized trial of an OMV-containing MenB vaccine against N gonorrhoeae infection did not show statistically significant vaccine efficacy, ongoing trials might shed further light. Several candidate vaccine antigens for a gonococcal-specific vaccine are being evaluated preclinically but only one has reached clinical trials.
引用
- Ruiz García Y, Marrazzo J, Martinón-Torres F, et al. Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context. J Infect Dis. 2024. PMID: 38819303. doi:10.1093/infdis/jiae289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。